文献速递心律失常

导管消融与胸腔镜外科消融治疗长程持续性房颤:CASA-AF随机对照试验

Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial.
PubMed 文献 · Eur Heart J · 2020-01-01

CASA-AF多中心随机对照试验纳入120例长程持续性房颤患者,比较胸腔镜外科消融与导管消融作为首次介入策略的疗效。12个月时单次手术无抗心律失常药物的房颤/房速复发率两组无显著差异(26% vs 28%),但导管消融症状改善更明显且质量调整生命年更多。

要点

  • 胸腔镜外科消融作为长程持续性房颤首次介入策略不优于导管消融。
  • 12个月单次手术无房颤/房速生存率外科消融26% vs 导管消融28%,无统计学差异。
  • 导管消融症状改善更显著且累积QALYs更多(0.78 vs 0.85,P=0.02)。

核心结论

  • 单次胸腔镜外科消融治疗长程持续性房颤不优于导管消融。
  • 导管消融在症状改善和QALYs方面优于外科消融。

研究设计与样本

  • 多中心随机对照试验,纳入120例长程持续性房颤患者,随机分配至外科消融或导管消融组。
  • 所有患者接受预定消融 lesion set 并植入植入式循环记录仪。

主要发现

  • 12个月单次手术无抗心律失常药物的房颤/房速(≥30秒)生存率:外科消融26%(14/54) vs 导管消融28%(17/60),OR 1.128(95%CI 0.46-2.83),P=0.83。
  • 房颤/房速负荷减少≥75%:外科消融67%(36/54) vs 导管消融77%(46/60),OR 1.13(95%CI 0.67-4.08),P=0.3。
  • 30天内手术相关严重不良事件:外科消融15%(8/55) vs 导管消融10%(6/60),P=0.46;外科消融组报告1例死亡。
  • 导管消融后房颤症状改善更显著。
  • 12个月内外科消融费用更高且QALYs更少(0.78 vs 0.85,P=0.02)。

临床怎么用

  • 对于长程持续性房颤患者,导管消融可作为首次介入策略的优先选择。
  • 外科消融虽可行但单次成功率与导管消融相当,且费用更高、QALYs更少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Long-standing persistent atrial fibrillation (LSPAF) is challenging to treat with suboptimal catheter ablation (CA) outcomes. Thoracoscopic surgical ablation (SA) has shown promising efficacy in atrial fibrillation (AF). This multicentre randomized controlled trial tested whether SA was superior to CA as the first interventional strategy in de novo LSPAF. METHODS AND RESULTS: We randomized 120 LSPAF patients to SA or CA. All patients underwent predetermined lesion sets and implantable loop recorder insertion. Primary outcome was single procedure freedom from AF/atrial tachycardia (AT) ≥30 s without anti-arrhythmic drugs at 12 months. Secondary outcomes included clinical success (≥75% reduction in AF/AT burden); procedure-related serious adverse events; changes in patients' symptoms and quality-of-life scores; and cost-effectiveness. At 12 months, freedom from AF/AT was recorded in 26% (14/54) of patients in SA vs. 28% (17/60) in the CA group [OR 1.128, 95% CI (0.46-2.83), P = 0.83]. Reduction in AF/AT burden ≥75% was recorded in 67% (36/54) vs. 77% (46/60) [OR 1.13, 95% CI (0.67-4.08), P = 0.3] in SA and CA groups, respectively. Procedure-related serious adverse events within 30 days of intervention were reported in 15% (8/55) of patients in SA vs. 10% (6/60) in CA, P = 0.46. One death was reported after SA. Improvements in AF symptoms were greater following CA. Over 12 months, SA was more expensive and provided fewer quality-adjusted life-years (QALYs) compared with CA (0.78 vs. 0.85, P = 0.02). CONCLUSION: Single procedure thoracoscopic SA is not superior to CA in treating LSPAF. Catheter ablation provided greater improvements in symptoms and accrued significantly more QALYs during follow-up than SA. CLINICAL TRIAL REGISTRATION: ISRCTN18250790 and ClinicalTrials.gov: NCT02755688.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Haldar S, Khan HR, Boyalla V, et al. Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial. Eur Heart J. 2020. PMID: 32860414. doi:10.1093/eurheartj/ehaa658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。